Literature DB >> 35217388

Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells.

Shikang Deng1, Li Zhang2, Jiao Li2, Yan Jin2, Junfeng Wang3.   

Abstract

Cholangiocarcinoma (CCA) is a primary biliary epithelium malignancy with limited therapies, poor prognosis and high mortality rate. Nowadays, the molecular mechanisms of CCA remain elusive. SPARC has been proposed to be highly expressed in clinical CCA tissues, but few studies has been elucidated its functions in CCA. In the current study, we aimed to investigate the functional role of SPARC in the progression of CCA. In this study, a significantly increased expression of SPARC was observed in CCA tissues and cells. Knockdown of SPARC by RNA interference significantly impeded the proliferation of CCA cells. Moreover, SPARC silencing hampered the migration and invasion of CCA cells by inhibiting EMT. In parallel, overexpression of SPARC in RBE cells had the opposite effects. Mechanically, SPARC promoted proliferation, migration, invasion, and EMT of CCA cells in vitro via activating the PI3K-AKT signaling. Overall, our integrated analysis revealed that SPARC plays a crucial role in CCA progression via the PI3K-AKT signaling pathway, which suggests that targeting SPARC might represent a promising approach for improving CCA patient's clinical outcome.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cholangiocarcinoma; PI3K-AKT signaling; SPARC

Year:  2022        PMID: 35217388     DOI: 10.1016/j.tice.2022.101756

Source DB:  PubMed          Journal:  Tissue Cell        ISSN: 0040-8166            Impact factor:   2.466


  2 in total

1.  Targeting Src-Hic-5 Signal Cascade for Preventing Migration of Cholangiocarcinoma Cell HuCCT1.

Authors:  Wen-Sheng Wu; Chin-Hsien Ling; Ming-Che Lee; Chuan-Chu Cheng; Rui-Fang Chen; Chen-Fang Lin; Ren-In You; Yen-Cheng Chen
Journal:  Biomedicines       Date:  2022-04-28

2.  DHW-208, A Novel Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Has Anti-Hepatocellular Carcinoma Activity Through Promoting Apoptosis and Inhibiting Angiogenesis.

Authors:  Shu Wang; Yuting Wu; Mingyue Liu; Qingchun Zhao; Lingyan Jian
Journal:  Front Oncol       Date:  2022-07-12       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.